HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Withold, W. Articles by Reinauer, H. Search for Related Content PubMed PubMed Citation Articles by Withold, W. Articles by Reinauer, H. Related Collections Proteomics and Protein Markers Endocrinology and Metabolism

Bone sialoprotein in serum of patients with malignant bone diseases

¹ Institut für Klinische Chemie und Laboratoriumsdiagnostik, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.

² Immundiagnostik GmbH, Bensheim, Germany.
^a Author for correspondence. Fax +49-211-81-18013; e-mail Richterb{at}uni-duesseldorf.de

Bone sialoprotein (BS), a protein synthesized by osteoblasts and osteoclasts and highly modified posttranslationally, constitutes a predominant fraction of the noncollagenous organic matrix in human bone. We report an assessment of serum concentrations of BS in patients with malignant bone diseases. In patients with bone metastases (according to scintigraphic criteria), serum BS concentrations were greater than in patients without bone metastases (P <0.05). However, ROC curve analysis revealed that serum BS was inferior to serum bone alkaline phosphatase in discriminating between patients with and without bone metastases. Patients with bone metastases showed a weak correlation between serum BS concentrations and bone formation markers. Only "traditional" markers of bone formation—but not BS—were correlated with urinary deoxypyridinoline (P <0.01). Liver and kidney dysfunction had no significant influence on BS values in these patients (as assessed by analysis of variance; P >0.05). In multiple myeloma patients treated with corticosteroids and bisphosphonates, BS concentrations were lower than in tumor patients without bone metastases (P <0.001), and the correlation between BS concentrations and the number of bisphosphonate courses applied was significant (r = -0.578; P <0.05). In postmenopausal women, serum BS concentrations averaged 142% greater than in premenopausal women. Further studies should be done, therefore, to elucidate whether serum BS is able to predict high bone turnover after menopause.

Key Words: indexing terms: alkaline phosphatase • carboxyl-terminal propeptide • deoxypyridinoline • urine • calcium • bone metastases • multiple myeloma • menopausal status • radioimmunoassay

The following articles in journals at HighWire Press have cited this article:

				I. J. Diel, E.-F. Solomayer, M. J. Seibel, J. Pfeilschifter, H. Maisenbacher, C. Gollan, M. Pecherstorfer, R. Conradi, G. Kehr, E. Boehm, et al. Serum Bone Sialoprotein in Patients with Primary Breast Cancer Is a Prognostic Marker for Subsequent Bone Metastasis Clin. Cancer Res., December 1, 1999; 5(12): 3914 - 3919. [Abstract] [Full Text] [PDF]

				B. Ganss, R.H. Kim, and J. Sodek Bone Sialoprotein Critical Reviews in Oral Biology & Medicine, January 1, 1999; 10(1): 79 - 98. [Abstract] [Full Text] [PDF]